Previous 10 | Next 10 |
home / stock / rhhby / rhhby articles
Roche Holding AG (OTC: RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge ...
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDA...
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally a...
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene m...
The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multipl...
Roche Holding AG (OTC: RHHBY) inked a deal to acquire Telavant Holdings, Inc. for $7.1 billion. As per the terms, Roche will pa...
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease...
Roche Holdings AG's (OTC: RHHBY) nine months sales increased by 1% (down 6% in CHF) to CHF 44.1 billion, even though the co...
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OT...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...